PRESENTED BY
Josua Jordi
NOMINATED BY
University of Zurich
Tags: Bye Bye Late Night Cravings, Swiss Start-ups, Pharma, Bio Tech, Metabolic Syndrome, Obesity, Appetite Supressors, First-in-class, Novel Drug Discovery Platform
Falling Walls
Falling Walls Science Summit 2023
Login or Register
You need to be logged in to use this feature.
Breaking the Wall of Uncontrolled Appetite
The Swiss biotech startup EraCal Therapeutics Ltd. aims to develop a novel anti-obesity drug Era-107 with demonstrated superior efficacy and tolerability compared to the standard of care in three vertebrate species – zebrafish, mice, and rat. EraCal, a spin-off from Harvard University and the University of Zurich, holds a worldwide exclusive license for the new chemical entity (patent filed Oct. 2018). An ambitious team with world-class advisors drives the development of Era-107, targeting first-in-human studies in H1/2022. Our zebrafish-based phenotypic screening platform is applicable to additional indications. EraCal secured CHF >1M in non-dilutive financing, won multiple awards (e.g. VentureKick, MIT life science angels award, IMD-startup competition, Nature SpinOff Prize finalist), and closed an oversubscribed CHF 6m seed round to finance the pre-clinical development of Era-107 and to broaden its pipeline in 2019.
Further Activities to have a look at